Stivarga
What Stivarga is used for
Stivarga is indicated as monotherapy for the treatment of adult patients with: metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy; unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib; hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Stivarga
- Active substance
- regorafenib
- Disease area
- Colorectal Neoplasms
- Medicine group
- Antineoplastic agents;Protein kinase inhibitors
- ATC code
- L01EX05
- Marketing authorisation holder
- Bayer Pharma AG
- Authorised in the EU since
- 2013
Official information
In the USA
Same active substance: Stivarga
In India
- Regorafenib: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Stivarga used for?
Stivarga is indicated as monotherapy for the treatment of adult patients with: metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy; unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib; hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
What is the active substance in Stivarga?
Stivarga contains regorafenib.
Who makes Stivarga?
The EU marketing authorisation holder is Bayer Pharma AG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU